This Scientist Is Building Custom Gene-Editing Tools—And Stands To Make Billions Benjamin Oakes' Scribe Therapeutics is developing specialized Crispr proteins for multiple diseases–and it’s got deals with Big Pharma potentially worth over $4 billion